What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 7 minute read Pharma Industry News GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more. byVenkateshMarch 9, 2026